Body fluid biomarkers and psychosis risk in The Accelerating Medicines Partnership® Schizophrenia Program
July 22, 2025
The Accelerating Medicines Partnership® Schizophrenia (AMP®SCZ) is a large-scale study designed to identify biomarkers that predict and explain clinical outcomes in individuals at clinical high risk (CHR) for psychosis. Nearly 2,000 CHR and 640 community participants will be followed for two years, with biomarker assessments at baseline and two months....
